3 studies found for:    18184952 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Enrolling by invitation Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
Conditions: Schizo-affective Disorder;   Bipolar Disorder
Interventions: Drug: glycine powder;   Drug: placebo
2 Recruiting Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP)
Conditions: 16p11.2 Deletions;   16p11.2 Duplications;   1q21.1 Deletions;   1q21.1 Duplications;   ADNP (ADNP1, KIAA0784);   ANKRD1 (ANCO1, T13, LZ16);   ARID1B (BAF250B);   ASXL3 (KIAA1713);   BAF105;   BAF180 (PBRM1, PB1);   BAF190 (SMARCA4/SMARCA2);   BAF35 (BCL7B);   BAF35b (ACTL6B);   BCL11A (CTIP1, EVI9, KIAA1809, FLJ10173);   CHD2;   CHD8 (KIAA1564, DUPLIN);   CTNNB1 (CTNNB);   CUL3 (Cullin 3, PHA2E, KIAA0617);   DST (BPAG1, BP240);   DYRK1A;   FOXP1 (QRF1);   GRIN2B (NMDAR2B, NR2B);   KDM6B (JMJD3, KIAA0346);   KMT2E (MLL5);   MBD5 (KIAA1461);   MED13L (THRAP2, PROSIT240, TRAP240L, KIAA1025);   PTEN (PTEN1, MMAC1);   REST (NRSF);   SCN2A;   SMARCC1 (BAF155);   SMARCC2 (BAF170);   SYNGAP1;   Additional Genetic Changes Associated With Autism May be Added as Identified
Intervention:
3 Enrolling by invitation Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
Conditions: Schizophrenia;   Bipolar Disorder
Interventions: Drug: D-cycloserine;   Drug: placebo

Indicates status has not been verified in more than two years